Myeloma Canada, along with thousands from the global hematology community, had the privilege of following the American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 – June 3) and the European Hematology Association (EHA) Hybrid Congress (June 13-16) to hear from leading myeloma experts about the latest progress in myeloma research.

The focus of the myeloma research presented was on belantamab mafodotin (Belamaf, an antibody-drug conjugate), quadruplet therapies with either daratumumab (Darzalex) or isatuximab (Sarclisa) in both transplant-eligible and ineligible newly diagnosed myeloma, bispecific antibody treatments, and chimeric antigen receptor (CAR) T-cell therapies. The results presented are a major step toward the potential Health Canada approval of belantamab mafodotin for relapsed/refractory myeloma, as well as the establishment of quadruplet therapies as the standard of care in newly diagnosed myeloma. In addition, bispecific antibody therapies and CAR T-cell therapies continue to show great efficacy and promise for the treatment of relapsed/refractory myeloma. 

Download the full update compiled by Myeloma Canada